# A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.

> **NCT00471159** · PHASE2 · WITHDRAWN · sponsor: **Pfizer**

## Conditions studied

- Breast Neoplasms

## Interventions

- **DRUG:** docetaxel
- **DRUG:** PF-3512676

## Key facts

- **NCT ID:** NCT00471159
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2007-08
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** 0 (ACTUAL)
- **Last updated:** 2015-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00471159

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00471159, "A Study Of Docetaxel Or Docetaxel Plus PF-3512676 To Treat Patients With Advanced Breast Cancer.". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00471159. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*